(usda loan mortgage companies, qualifications for a conventional mortgage loan, mortgage home loan process, va mortgage loan credit score requirements, what is the mortgage rate for a va loan, how to apply for a va mortgage loan, mortgage loan omaha, movement mortgage va loan, sierra pacific mortgage my home loan, when to refinance mortgage loan, how much is a jumbo mortgage loan, mortgage loan options for first time home buyers, mortgage loan income to debt ratio, what does it take to be a mortgage loan officer, refinance mortgage and equity loan, qualify for a fha mortgage loan, second mortgage or home equity loan, advantages of a va mortgage loan, va mortgage loan closing costs, apply for mortgage loan online with bad credit, mortgage loan disclosures within 3 days, how to get home mortgage loan, federal home loan mortgage company, prequalify for mortgage loan online, refinance mortgage vs home equity loan, citigroup mortgage loan trust inc phone number, mortgage loan pre approval online, mortgage loan expenses, apply online for mortgage loan, second mortgage loan companies, harp loan second mortgage, fha loan without mortgage insurance, home loan mortgage broker, can i refinance my mortgage and home equity loan together, what is the maximum loan amount for a reverse mortgage, 200k loan mortgage, can i get a home improvement loan with my mortgage, 21st mortgage loan requirements, no mortgage home equity loan, pre approved mortgage but denied loan, bank or mortgage company for home loan, mortgage loan grants, va loan mortgage companies, 100 loan to value mortgage refinance, mortgage loan rate vs apr, veterans mortgage loan, estimate mortgage loan approval amount, who can get a va mortgage loan, is a home equity loan the same as a mortgage, va mortgage loan eligibility, difference between mortgage and home loan, reverse mortgage loan rates, reverse mortgage home loan, reverse mortgage loan scheme sbi, best cheapest car insurance company, who is the best car insurance company for young drivers, best term insurance company, best online car insurance company, best insurance company for drivers with points, best cheap car insurance company, best company for auto insurance, best cheapest auto insurance company, best car insurance company for new drivers, best company for car insurance, cheapest best auto insurance company, which is the best insurance company for auto, what is the best home and auto insurance company, what is the best and cheapest auto insurance company, best and cheapest car insurance company, best company for home and auto insurance, navigators insurance company am best rating, best car insurance company 2015, what is the best insurance company for auto, best car insurance company california, what is the cheapest and best car insurance company, best car insurance company in california, best online insurance company, who is the best rated auto insurance company, best insurance company for auto and home, automotive accident lawyers, accident automotive, automotive insurance company, cheap automotive insurance, automotive insurance, automotive insurance quotes, automotive insurance new york, automotive insurance companies, automotive certification online)

DIAGNOS Gets the Green Light for the Use of its Diabetic Retinopathy Screening Technology in Quebec Hospitals

DIAGNOS receives green light to deploy its diabetic retinopathy screening technology in Quebec hospitals

BROSSARD, Quebec, January 31, 2023 (GLOBE NEWSWIRE) — Diagnos Inc. (”


“, the ”


“or “we”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in the early detection of critical health issues through the use of its FL


RE platform based on artificial intelligence (


), is pleased to announce that the Government of Quebec has given the go-ahead for Diagnos artificial intelligence (AI) technology to screen and assess diabetic retinopathy patients identified by the endocrinology departments of hospitals across the province be taken care of.

DIAgnos receives approval for Quebec hospitals

This positive milestone is the result of a collaborative project initiated in 2018 using Diagnos’ technology to assess and classify the severity of diabetic retinopathy in patients in the endocrinology department of a major Quebec hospital.

The pilot phase of the project was successfully completed, leading to the preparation of a final report by government officials. This report has been distributed to all hospitals in the province and highlights the cost savings and other benefits of implementing DIAGNOS technology. Specifically, the report found that the use of DIAGNOS’ technology resulted in cost savings of $85 per patient, as well as additional savings from optimizing and reducing the time spent by medical staff.

“The project has been a long but rewarding journey for DIAGNOS, especially given the COVID-19 restrictions in the hospital’s endocrinology and ophthalmology departments. We are delighted that the government is recognizing the value of our AI-based diabetic retinopathy screening solution. DIAGNOS will now start marketing it to all hospitals and clinics in the province,” he says


André Larente, President of DIAGNOS


Larente continued, “We have been working tirelessly on this project since 2018 and are excited to bring Diagnos’ innovative solutions to the people of Quebec, especially given the province’s high rate of diabetes. Our solutions will make early detection and prevention of vision loss more accessible to the population, which is critical to the health and well-being of people with diabetes.”

According to Statistics Canada, Quebec has one of the highest rates of diabetes in the country, with over 1 million people living with diabetes. With such a large population of diabetics receiving endocrinology services in Quebec hospitals, the market potential for DIAGNOS’ AI screening solutions is significant.


DIAGNOS is a publicly traded Canadian company dedicated to the early detection of critical health issues based on its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for rapid modification and development of applications such as CARA (Computer Assisted Retina Analysis). CARA’s image enhancement algorithms deliver sharper, clearer and easier to analyze retinal images. CARA is a cost-effective tool for real-time screening of large patient populations. CARA has been cleared for marketing by the following regulatory agencies: Health Canada, FDA (US), CE (Europe), COFEPRIS (Mexico), and Saudi FDA (Saudi Arabia).

For more information, see




For more information please contact:

Mr André Larente, President


Tel: 450 678-8882, ext. 224

Email: [email protected]

This press release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this press release is expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/87001ed4-5039-44c7-a5aa-dc862016216b

Primary logo

Leave a Reply

Your email address will not be published. Required fields are marked *

| |
Back to top button